{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:24:53Z","timestamp":1780514693098,"version":"3.54.1"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005315","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2023J195"],"award-info":[{"award-number":["2023J195"]}],"id":[{"id":"10.13039\/501100005315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017356","name":"Ningbo Municipal Innovation Team of Life Science and Health","doi-asserted-by":"publisher","award":["2023Y49"],"award-info":[{"award-number":["2023Y49"]}],"id":[{"id":"10.13039\/100017356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs), particularly programmed cell death protein 1 (PD-1) inhibitors, are widely used in oncology but can cause immune-related adverse events, including hepatotoxicity. Severe ICI-induced liver injury progressing to acute or subacute liver failure carries a poor prognosis and presents a significant management challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We present the case of a 58-year-old male with recurrent nasopharyngeal carcinoma who developed severe autoimmune hepatitis and subacute liver failure following his first cycle of tislelizumab (an anti-PD-1 antibody) combined with chemotherapy. Despite initial management with corticosteroids and hepatoprotective agents, his liver function deteriorated rapidly, characterized by progressive hyperbilirubinemia and coagulopathy. After transfer to a tertiary center, he was managed with high-dose intravenous methylprednisolone, mycophenolate mofetil, and three sessions of artificial liver support (plasma exchange and bilirubin adsorption). His liver function gradually stabilized and ultimately recovered. At follow-up, he achieved normal liver biochemistry and a good quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores the potential severity of ICI-induced hepatotoxicity. It highlights the critical importance of early recognition, prompt grading according to guidelines (e.g., CSCO), and aggressive, multimodal immunosuppressive therapy combined with artificial liver support in managing life-threatening immune-mediated liver failure. Close monitoring of liver function before, during, and after ICI therapy is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1806957","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:43:29Z","timestamp":1777351409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful diagnosis and treatment of autoimmune hepatitis leading to liver failure following PD-1 immunotherapy in a patient with nasopharyngeal carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yu","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Beilun District People\u2019s Hospital of Ningbo City (Beilun Branch of the First Affiliated Hospital of Zhejiang University School of Medicine)","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beilun District People\u2019s Hospital of Ningbo City (Beilun Branch of the First Affiliated Hospital of Zhejiang University School of Medicine)","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Beilun District People\u2019s Hospital of Ningbo City (Beilun Branch of the First Affiliated Hospital of Zhejiang University School of Medicine)","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Beilun District People\u2019s Hospital of Ningbo City (Beilun Branch of the First Affiliated Hospital of Zhejiang University School of Medicine)","place":["Ningbo, Zhejiang, China"]},{"name":"Department of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-4985.2022.30.003","article-title":"Clinical efficacy of tislelizumab combined with induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients","volume":"19","author":"Guo","year":"2022","journal-title":"Med Innovation China"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20240115-00018","article-title":"Chinese expert consensus on diagnosis and treatment of immune checkpoint inhibitor-related liver injury (2024 edition)","volume":"32","author":"Wang","year":"2024","journal-title":"Chin J Hepatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s12072-023-01567-x","article-title":"Management of corticosteroid-refractory immune checkpoint inhibitor-related hepatitis: A multicenter retrospective study","volume":"17","author":"Kong","year":"2023","journal-title":"Hepatol Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1001823","article-title":"Artificial liver support system as a bridge therapy in immune checkpoint inhibitor-induced acute liver failure: A case series and literature review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B6","volume-title":"Guidelines for toxicity management of immune checkpoint inhibitors 2023","year":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100170","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"Martin","year":"2020","journal-title":"JHEP Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101619","article-title":"The current status of steroid-refractory immune-checkpoint-inhibitor-related hepatotoxicity","volume":"28","author":"Xing","year":"2023","journal-title":"Transl Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-5069.2022.03.039","article-title":"Expert consensus on clinical application of artificial liver blood purification technology (2022 edition)","volume":"25","author":"Bai","year":"2022","journal-title":"J Pract Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20230419-00176","article-title":"Guidelines for diagnosis and treatment of drug-induced liver injury in China (2023 edition)","volume":"31","year":"2023","journal-title":"Chin J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23588","article-title":"Drug-induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"Bj\u00f6rnsson","year":"2010","journal-title":"Hepatology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:43:52Z","timestamp":1777351432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":12,"alternative-id":["10.3389\/fonc.2026.1806957"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1806957","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"article-number":"1806957"}}